Australian Group on Antimicrobial Resistance (AGAR)
The Australian Group on Antimicrobial Resistance (AGAR) is a collaboration of clinicians and scientists from key microbiology laboratories around Australia and includes metropolitan and rural, and private and public sites. AGAR conducts targeted surveillance of selected pathogens that cause bloodstream infections and collects demographic, treatment and outcome data, and data on antimicrobial resistance (AMR) rates. AGAR is an important, core component of the Antimicrobial Use and Resistance (AURA) Surveillance System.
The Australian Society for Antimicrobials (ASA) coordinates AGAR to collect, analyse and report on data submitted by participating laboratories.
Laboratories participate in AGAR surveys by providing laboratory data and isolates to AGAR coordinating laboratories. These AGAR laboratories collate the data and undertake molecular testing on isolates. AGAR prepares annual reports for the following three programs, formerly known as Sepsis Outcome Programs:
- Australian Enterococcus Surveillance Outcome Program (AESOP)
- Australian Staphyloccoccal Surveillance Outcome Program (ASSOP)
- Gram-negative Surveillance Outcome Program (GnSOP)
AGAR publishes a range of articles, presentations and reports on its website.
The 2021 AGAR Amalgam Surveillance Outcome Programs Report is now available below.
Surveillance Outcome Programs reports
AGAR collaborates with the Commission to prepare reports for AURA that bring together the key findings of the three Surveillance Outcome Programs, formerly Sepsis Outcome Programs, as a means of increasing access to AMR surveillance data to inform response strategies and improve the safety and quality of care provided to patients.
Surveillance Outcome Programs fact sheets
The Commission and AGAR have collaborated on detailed analyses of data relating to methicillin-resistant Staphylococcus aureus (MRSA) bacteraemias, including changes in the clones that cause MRSA disease.